195 related articles for article (PubMed ID: 20357493)
1. Evaluation of a 6-year highly active antiretroviral therapy in Chinese HIV-1-infected patients.
Zhou HY; Zheng YH; He Y; Chen Z; Liu M; Yin W; Liu C
Intervirology; 2010; 53(4):240-6. PubMed ID: 20357493
[TBL] [Abstract][Full Text] [Related]
2. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
[TBL] [Abstract][Full Text] [Related]
3. Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO study.
Reliquet V; Allavena C; François-Brunet C; Perré P; Bellein V; Garré M; May T; Souala F; Besnier JM; Raffi F
HIV Med; 2006 Oct; 7(7):431-6. PubMed ID: 16925728
[TBL] [Abstract][Full Text] [Related]
4. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.
Arranz Caso JA; López JC; Santos I; Estrada V; Castilla V; Sanz J; Sanz J; Molina JP; Fernández Guerrero M; Górgolas M
HIV Med; 2005 Sep; 6(5):353-9. PubMed ID: 16156884
[TBL] [Abstract][Full Text] [Related]
5. [Therapeutic effect and safety evaluation on 6-year highly active antiretroviral therapy for Chinese HIV-1 infected patients].
Zhou H; Zheng Y; He Y; Gong G; Chen Z; Liu M; Yin W; Liu C
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Aug; 34(8):731-7. PubMed ID: 19734579
[TBL] [Abstract][Full Text] [Related]
6. Impact of baseline CD4(+) T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study.
Liu ZY; Guo FP; Han Y; Qiu ZF; Zuo LY; Li YL; Li TS
Chin Med J (Engl); 2009 Oct; 122(20):2497-502. PubMed ID: 20079166
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of protease inhibitor switching to nevirapine in HIV-infected patients with undetectable virus load.
Gil P; de Górgolas M; Estrada V; Arranz A; Rivas P; Yera C; García R; Granizo JJ; Fernández-Guerrero M
Clin Infect Dis; 2004 Oct; 39(7):1024-9. PubMed ID: 15472856
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
Ribera E; Rodríguez-Pardo D; Rubio M; Soler A; Pedrol E; Blanco JL; González A; Crespo M; Falcó V; Ocaña I; Deig E; Miró JM; Pahissa A
Antivir Ther; 2005; 10(5):605-14. PubMed ID: 16152754
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of highly active antiretroviral therapy in HIV-1 infected children in Kenya.
Song R; Jelagat J; Dzombo D; Mwalimu M; Mandaliya K; Shikely K; Essajee S
Pediatrics; 2007 Oct; 120(4):e856-61. PubMed ID: 17846147
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study.
Manosuthi W; Chumpathat N; Chaovavanich A; Sungkanuparph S
BMC Infect Dis; 2005 Aug; 5():67. PubMed ID: 16120209
[TBL] [Abstract][Full Text] [Related]
11. Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine.
Plana M; Ferrer E; Martínez C; Podzamczer D; García F; Maleno MJ; Barceló JJ; García A; Barberá MJ; Lacarcel M; Miró JM; Gallart T; Gatell JM
Antivir Ther; 2004 Apr; 9(2):197-204. PubMed ID: 15134181
[TBL] [Abstract][Full Text] [Related]
12. Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA.
Achenbach CJ; Till M; Palella FJ; Knoll MD; Terp SM; Kalnins AU; Murphy RL
HIV Med; 2005 Jan; 6(1):7-12. PubMed ID: 15670246
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
[TBL] [Abstract][Full Text] [Related]
14. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients.
Ruiz L; Paredes R; Gómez G; Romeu J; Domingo P; Pérez-Alvarez N; Tambussi G; Llibre JM; Martínez-Picado J; Vidal F; Fumaz CR; Clotet B;
AIDS; 2007 Jan; 21(2):169-78. PubMed ID: 17197807
[TBL] [Abstract][Full Text] [Related]
15. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
Moore RD; Keruly JC
Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
[TBL] [Abstract][Full Text] [Related]
16. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and adverse effects of GPO-VIR (stavudine+lamivudine+nevirapine) in treatment-naïve adult HIV patients.
Tin EE; Bowonwatanuwong C; Desakorn V; Wilairatana P; Krudsood S; Pitisuttithum P
Southeast Asian J Trop Med Public Health; 2005 Mar; 36(2):362-9. PubMed ID: 15916042
[TBL] [Abstract][Full Text] [Related]
18. Virologic outcomes of first-line HAART and associated factors among Chinese patients with HIV in three sentinel antiretroviral treatment sites.
Ruan Y; Xing H; Wang X; Tang H; Wang Z; Liu H; Su B; Wu J; Li H; Liao L; Li J; Wu JW; Shao Y
Trop Med Int Health; 2010 Nov; 15(11):1357-63. PubMed ID: 20868414
[TBL] [Abstract][Full Text] [Related]
19. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).
Podzamczer D; Ferrer E; Consiglio E; Gatell JM; Perez P; Perez JL; Luna E; González A; Pedrol E; Lozano L; Ocaña I; Llibre JM; Casiró A; Aranda M; Barrufet P; Martínez-Lacasa J; Miró JM; Badía X; Casado A; Lupo S; Cahn P; Maños M; Estela J
Antivir Ther; 2002 Jun; 7(2):81-90. PubMed ID: 12212928
[TBL] [Abstract][Full Text] [Related]
20. Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).
Negredo E; Miró O; Rodríguez-Santiago B; Garrabou G; Estany C; Masabeu A; Force L; Barrufet P; Cucurull J; Domingo P; Alonso-Villaverde C; Bonjoch A; Morén C; Pérez-Alvarez N; Clotet B;
Clin Infect Dis; 2009 Sep; 49(6):892-900. PubMed ID: 19663689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
